Current therapy of inflammatory bowel disease in children

Pediatric Drugs

Volumn 8, Issue 5, 2006, Pages 279-302

  Rufo, Paul A ^a   Bousvaros, Athos ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOSPORIN; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; THALIDOMIDE; TSUKUBAENOLIDE; UNINDEXED DRUG;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACHILLES TENDON RUPTURE; ACNE; ADRENAL SUPPRESSION; ANEMIA; BACTERIAL INFECTION; BLOODY DIARRHEA; BONE MARROW TOXICITY; CANCER; CANCER RISK; CANCER SCREENING; CATARACT; CHEST TIGHTNESS; CLINICAL TRIAL; COLITIS; COLON CANCER; COLON RESECTION; COLONOSCOPY; CONGENITAL MALFORMATION; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CROHN DISEASE; DIAGNOSTIC TEST; DIARRHEA; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DYSPHAGIA; DYSPNEA; ENTERITIS; FACE EDEMA; FATIGUE; FEVER; FLUSHING; FOLIC ACID DEFICIENCY; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; ILEOSTOMY; INCIDENCE; INTERSTITIAL NEPHRITIS; IRON DEFICIENCY; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MALNUTRITION; MENTAL DISEASE; META ANALYSIS; MOON FACE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOLYSIS; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROCTITIS; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RASH; RELAPSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TENDON DISEASE; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VITAMIN D DEFICIENCY; VOMITING; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NUTRITION DISORDERS; PROBIOTICS;

EID: 33750217972     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608050-00002     Document Type: Review

References (221)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115 (1): 182-205
2. Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004; 13 Suppl. 1: R161-8
3. Girardin SE, Travassos LH, Herve M, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003; 278 (43): 41702-8
4. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998; 42 (3): 309-11
5. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34 (12): 1841-54
6. Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143: 525-31
7. Bousvaros A, Murray K, Leichtner A. Clinical manifestations and diagnosis of Crohn's disease in children and adolescents [online]. Available from URL: http://www.uptodate.com [Accessed 2006 Sep 27]
8. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98 (6): 1309-14
9. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13 (2): 279-84
10. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47 (4): 506-13
11. Vaishnavi C, Bhasin DK, Singh K. Fecal lactoferrin assay as a cost-effective tool for intestinal inflammation. Am J Gastroenterol 2000; 95 (10): 3002-3
12. Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002; 97 (2): 360-9
13. van der Sluys Veer A, Biemond I, Verspaget HW, et al. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 106-10
14. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91 (5): 927-34
15. Bousvaros A, Leichtner A. Overview of the management of Crohn's disease in children and adolescents [online]. Available from URL: http://www.uptodate. com [Accessed 2006 Sep 27]
16. Kornbluth AA, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993; 16: 215-8
17. Crohn's and Colitis Foundation of America. Medications for inflammatory bowel disease, 2003 [online]. Available from URL: http://www.ccfa.org/info/ brochures [Accessed 2006 Sep 27]
18. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalzine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993; 17: 32-8
19. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97 (12): 3078-86
20. Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis: the Abacus Investigator Group. Gastroenterology 1998; 114 (1): 15-22
21. Gilat T, Suissa A, Leichtman G, et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis: an Israeli multicenter trial. J Clin Gastroenterol 1987; 9 (4): 415-7
22. Davies PS, Rhodes J, Heatley RV, et al. Metronidazole in the treatment of chronic proctitis: a controlled trial. Gut 1977; 18 (8): 680-1
23. Gilat T, Leichtman G, Delpre G, et al. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989; 11 (4): 392-5
24. Turunen U, Farkkila MA, Valtonen V. Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 1999; 117 (1): 282-3
25. Rowe FA, Walker JH, Karp LC, et al. Factors predictive of response to cyclosporine treatment for severe, steroid resistant ulcerative colitis. Am J Gastroenterol 2000; 95 (8): 2000-8
26. Werlin SL, Grand R. Severe colitis in children and adolescents: diagnosis, course, treatment. Gastroenterology 1977; 73: 828-32
27. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-9
28. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5
29. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125 (4): 1025-31
30. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4 (4): 276-9
31. Naftali T, Novis B, Pomeranz I, et al. Cyclosporine treatment for severe ulcerative colitis. Isr Med Assoc J 2000; 2: 588-91
32. Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991; 119 (6): 994-7
33. Barabino A, Torrente F, Castellano E, et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther 2002; 16 (8): 1503-7
34. Cohn RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94 (6): 1587-92
35. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41 (12): 2471-6
36. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996; 23 (3): 329-33
37. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137 (6): 794-9
38. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8 (5): 317-24
39. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18 (4): 415-23
40. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17 (10): 1273-81
41. Ogata II, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 Sep; 55 (9): 1255-62
42. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94 (6): 1587-92
43. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 Dec 8; 353 (23): 2462-76
44. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002; 34 (3): 307-11
45. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004 Aug; 39 (2): 166-70
46. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204-11
47. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9 (3): 293-300
48. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85 (9): 1079-82
49. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15 (2): 251-6
50. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. US Budesonide Enema Study Group. Gastroenterology 1998; 115 (3): 525-32
51. Danielsson A, Hellers G, Lyrenas E, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22 (8): 987-92
52. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40 (6): 775-81
53. Lee FL, Jewell DP, Mani V, et al. A randomized trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996; 38: 229-33
54. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429-35
55. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; (4): CD000544
56. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-78
57. Ferry GD. Aminosalicylates in the treatment of children with inflammatory bowel disease: summary of the workshop on aminosalicylate pharmacology. Inflamm Bowel Dis 1998; 4 (2): 113-4
58. Biddle WL, Greenberger NJ, Swan JT, et al. 5-aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075-9
59. d'Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990; 33: 394-7
60. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-7
61. George J, Present DH, Pou R. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91 (9): 1711-4
62. Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999; 28 (1): 54-8
63. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117 (5): 809-14
64. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 Suppl. 1: S30-8
65. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (4): 705-13
66. Farrell RJ, Peppercorn MA. Medical management of Crohn's disease in adults [online]. Available from URL: http://www.uptodate.com [Accessed 2006 Sep 27]
67. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003; 9 (1): 34-58
68. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108 (4): 1056-67
69. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31 (1): 8-15
70. Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 31 (1): 3-5
71. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002; 97 (4): 803-23
72. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20 (2): 167-72
73. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104 (5): 1293-301
74. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89 (5): 692-8
75. Hildebrand H, Berg NO, Hoevels J, et al. Treatment of Crohn's disease with metronidazole in childhood and adolescence: evaluation of a six months trial. Gastroenterol Clin Biol 1980; 4 (1): 19-25
76. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83 (3): 550-62
77. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease: Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94 (3): 674-8
78. McKeage K, Goa KL. Budesonide (Entocort EC capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002; 62 (15): 2263-82
79. Mack DR, Young R, Kaufmann SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132 (5): 830-5
80. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97 (12): 2962-72
81. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37 (5): 674-8
82. Bouhnik Y, Lemann M, Mary J, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347 (8996): 215-9
83. Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108 (5): 1427-33
84. Kugathasan S, Werlin SI, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000 Nov; 95 (11): 3189-94
85. Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. Am J Gastroenterol 1989; 84 (3): 249-54
86. Dejaco C, Harper M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18 (11-12): 1113-20
87. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83 (2): 383-7
88. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985; 30 (1): 58-64
89. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340 (18): 1398-405
90. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39 (2): 374-80
91. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108 (6): 1617-21
92. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99 (4): 956-63
93. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976; 11 (7): 651-6
94. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol 2000; 95 (5): 1139-46
95. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113 (5): 1465-73
96. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease: Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8 (1): 35-43
97. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use 1990-2000. Am J Gastroenterol 2002; 97 (4): 928-32
98. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127 (3): 723-9
99. Ardizzone S, Maconi G, Sampieto GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127 (3): 730-40
100. Peppercorn MA. Sulfasalazine. Ann Intern Med 1984; 101 (3): 377-86
101. Kalogeris T, Grisham MB. Mode of action of anti-inflammatory agents. In: Bayless TM, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. London: BC Decker Inc., 2001: 63-7
102. Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000; 47 (31): 71-82
103. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101 (5): 1163-74
104. Pearson DC, Jourd'heuil D, Meddings JB. The anti-oxidant properties of 5-aminosalicylic acid. Free Radic Biol Med 1996; 21 (3): 367-73
105. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28 (2): 190-5
106. Barden L, Lipson A, Pert P, et al. Mesalazine in childhood inflammatory bowel disease. Aliment Pharmacol Ther 1989; 3 (6): 597-603
107. Radke M, Bartolomaeus G, Muller M, et al. Acute pancreatitis in Crohn's disease due to 5-ASA therapy. J Pediatr Gastroenterol Nutr 1993; 16 (3): 337-9
108. D'Agata ID, Vanounou T, Siedman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis 1996; 2: 229-35
109. Boyer DL, Li BU, Fyda JN, et al. Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1989; 8 (4): 528-32
110. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51 (4): 536-9
111. Goldstein F, DiMarino Jr AJ. Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease. J Clin Gastroenterol 2000; 31 (1): 60-2
112. Solem CA, Tremaine WJ. Sequential and combination therapy for ulcerative colitis. In: Bayless TM, Hanauer SB, editors. Seminars in inflammatory bowel disease. New York: Crohn's and Colitis Foundation of America, 2003
113. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42 (4): 477-84
114. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118 (5): 859-66
115. Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Inflamm Bowel Dis 2001; 7 Suppl. 1: S23-9
116. Bousvaros A. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm Bowel Dis 2004; 10 (4): 481-3
117. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98 (4): 811-8
118. Lundin PD, Edsbacker S, Bergstrand M, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther 2003; 17 (1): 85-92
119. Keller R, Stoll R, Foerster EC, et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997; 11 (6): 1047-52
120. Kundhal P, Zachos M, Holmes JL, et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001; 33 (1): 75-80
121. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2002; 36: 248-52
122. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002; 140 (1): 75-80
123. Levine A, Watermberg N, Hager H, et al. Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease. J Child Neurol 2001; 16 (6): 458-61
124. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16 (1): 47-54
125. Krook A, Jamerot G, Danielsson D. Clinical effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora. Scand J Gastroenterol 1981; 16: 569-75
126. Gnarpe H, Belsheim J, Persson S. Influence of nitroimidazole derivatives on leukocyte migration. Scand J Infect Dis Suppl 1981; 26: 68-71
127. Grove DI, Mahmound AA, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 1977; 54 (5): 422-7
128. Muller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 1983; 93 (1 Pt 2): 165-71
129. Smilack JD, Wilson WR, Cockerill III FR. Tetracyclines, chloramphenicol, erythromycin, clindamycin, metronidazole. Mayo Clin Proc 1991; 66 (12): 1270-80
130. Corey WA, Doebbeling BN, DeJong KJ, et al. Metronidazole-induced acute pancreatitis. Rev Infect Dis 1991; 13 (6): 1213-5
131. Finegold SM. Metronidazole. Ann Intern Med 1980; 93 (4): 585-7
132. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonograpic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004 Dec; 20 (11-12): 1329-36
133. Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002 Jan; 8 (1): 10-5
134. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36 (11): 1404-10
135. Segev S, Yaniv I, Haverstock D, et al. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis 1999; 28 (2): 299-308
136. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000; 22 (6): 479-85
137. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, prebiotics. Gastroenterology 2004; 126 (6): 1620-33
138. Rajapakse R, Korelitz BI. Azathiprine and 6-mercaptopurine use in Crohn's disease. In: Bayless TM, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. London: BC Decker Inc., 2001: 373-7
139. Cuffari C. Azathioprine metabolism in inflammatory bowel disease: correlation with efficacy and toxicity. In: Bayless TM, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. London: BC Decker Inc., 2001: 377-81
140. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39 (4): 456-9
141. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990; 99 (5): 1347-51
142. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119 (4): 895-902
143. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30 (3): 294-8
144. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112 (5): 1475-81
145. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115 (4): 813-21
146. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343 (8908): 1249-52
147. Dayharsh GA, Loftus Jr EV, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122 (1): 72-7
148. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118 (6): 1018-24
149. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111 (8): 641-9
150. Laurentaci G, Catalano G, Chiumarulo C, et al. Immunosuppressive action and effects of amethopterin on the lymphoid tissue of the rabbit appendix. Minerva Med 1980; 71 (2): 103-10
151. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92 (6): 2675-82
152. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Study Group Investigators. N Engl J Med 2000; 342 (22): 1627-32
153. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators. N Engl J Med 1995; 332 (5): 292-7
154. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46 (27): 1724-9
155. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92 (12): 2203-9
156. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110 (5): 1416-21
157. Weinblatt ME. Methotrexate for chronic diseases in adults. N Engl J Med 1995; 332 (5): 330-1
158. Lemann M, Zenjan T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95 (7): 1730-4
159. Feagan BG, Kumaranayake P. Methotrexate in inflammatory bowel disease. In: Bayless TM, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. London: BC Decker Inc, 2001: 383-6
160. Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37 (3): 316-28
161. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13 (4): 136-42
162. Ina K, Kusugami K, Shimada M, et al. Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis. Inflamm Bowel Dis 2002; 8 (1): 1-9
163. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120 (6): 1323-9
164. Procupek DA, Kashyap PK, Targan SR, et al. Cyclosporin in the treatment of refractory UC: clinical determinants of a successful outcome after 6 months [abstract]. Gastroenterology 1994; 106 Suppl. A: A756
165. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children: immediate response, long-term results, impact on surgery. Dis Colon Rectum 1995; 38 (5): 474-9
166. Treem WR, Cohen J, Davis PM, et al. Cyclosporine treatment for the treatment of fulminant ulcerative colitis in children. Dis Colon Rectum 1994; 38 (5): 474-8
167. McCormack G, McCormick PA, Hyland JM, et al. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort? Dis Colon Rectum 2002; 45 (9): 1200-5
168. Cohen RD. Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology 2001; 120 (6): 1541-3
169. Vincent F, Bensousan TA. Cyclosporine in severe ulcerative colitis [letter]. N Engl J Med 1995; 332 (2): 127
170. Taylor AC, Connell WR, Elliott RR, et al. Oral cyclosporine in refractory inflammatory bowel disease. Aust J Med 1998; 28: 179-83
171. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121 (5): 1145-57
172. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003; 12 (7): 1087-95
173. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541-9
174. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9): 876-85
175. Present DH. The efficacy of infliximab in Crohn's disease: healing of fistulae. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 23-8
176. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98 (4): 833-8
177. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003; 18 (7): 741-7
178. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006 May; 4 (5): 621-30
179. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for
180. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17 (1): 75-84
181. Baumgart DC, Dignass AU. Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy? Z Gastroenterol 2003; 41 (5): 478-9
182. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363 (9423): 1802-11
183. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117 (6): 1271-7
184. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117 (6): 1278-87
185. Bariol C, Meagher AP, Vickers CK, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17 (2): 135-9
186. Kho YH, Pool MO, Jansman FG, et al. Pharmacotherapeutic options in inflamamatory bowel disease: an update. Pharm World Sci 2001; 23 (1): 17-21
187. Neurath MF, Wanitschke R, Peters M, et al. Mycophenolate mofetil for treatment of active inflammatory bowel disease: clinical and immunological studies. Ann N Y Acad Sci 1998; 859: 315-8
188. Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14 (2): 171-6
189. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95 (5): 1201-7
190. Ford AC, Towler RJ, Moayyedi P, et al. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17 (11): 1365-9
191. Youdim A, Vasiliauskasea EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10 (4): 333-8
192. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 Feb; 130 (2): 323-33
193. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003; 98 (11): 2372-82
194. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS: the UK Antegren Study Group. Neurology 1999; 53 (3): 466-72
195. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16 (4): 699-705
196. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121 (2): 268-74
197. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348 (1): 24-32
198. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18 (1): 65-75
199. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98 (2): 369-76
200. Venturi A, Gionchetti P, Pizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13 (8): 1103-8
201. Kruis W, Schultz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11 (5): 853-8
202. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354: 635-9
203. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25 (4): 653-8
204. Guandalini S. Use of Lactobacillus-GG in paediatric Crohn's disease. Dig Liver Dis 2002; 34 Suppl. 2: S63-5
205. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31 (4): 453-7
206. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005 Sep; 11 (9): 833-9
207. Gionchetti P, Rizello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124 (5): 1202-9
208. Gionchetti P, Rizello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119 (2): 305-9
209. Strobel CT, Byrne WJ, Ament ME. Home parenteral nutrition in children with Crohn's disease: an effective management alternative. Gastroenterology 1979; 77 (2): 272-9
210. Morin CL, Roulet M, Roy CC, et al. Continuous elemental enteral alimentation in the treatment of children and adolescents with Crohn's disease. J Parenter Enteral Nutr 1982; 6 (3): 194-9
211. Navarro J, Vargas J, Cezard JP, et al. Prolonged constant rate elemental enteral nutrition in Crohn's disease. J Pediatr Gastroenterol Nutr 1982; 1 (4): 541-6
212. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38 (4): 543-8
213. Chinea B, Rosa A, Oharriz JJ, et al. Osteopenia in Puerto Ricans with Crohn's disease. P R Health Sci J 2000; 19 (4): 329-33
214. Murray JJ. Ulcerative colitis: indications for elective colectomy. In: Allan RN, Keighley MRB, Rhodes J, et al. editors. Inflammatory bowel diseases. New York: Churchill Livingstone, 1997: 733-40
215. Mignon M, Settler C, Phillips SF. Pouchitis: a poorly understood entity. Dis Colon Rectum 1995; 38: 100-3
216. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastamosis: a pouch disease activity index. Mayo Clin Proc 1994; 69: 409-15
217. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7 (4): 301-5
218. Fonkalsrud EW. Surgery for pediatric ulcerative colitis. Curr Opin Pediatr 1995; 7 (3): 323-7
219. Mekhjian HS, Switz DM, Watts HD, et al. National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979; 77 (4 Pt 2): 907-13
220. Chardavoyne R, Flint GW, Pollack S, et al. Factors affecting recurrence following resection for Crohn's disease. Dis Colon Rectum 1986; 29 (8): 495-502
221. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol 2003; 17 (1): 63-73